Category - Developments

Developments

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...

November 12, 2025

Developments

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...

November 11, 2025

Developments

Precision presents late-breaking Phase 1 BDGENE-HBV data at AASLD

Precision BioSciences (NASDAQ: DTIL) announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, to be delivered by Dr. Man-Fung Yuen, Chair...

November 11, 2025

Developments

Altimmune’s Phase 2 IMPACT trial data published in The Lancet

Altimmune (NASDAQ: ALT) has announced publication of 4-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in The...

November 11, 2025

Developments

Profound regains distribution rights for TULSA-PRO in Canada

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) has announced that it has regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics (TSX: GUD). Under the agreement established with Knight...

November 11, 2025

Developments

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Closely held PharmaJet has announced that it has signed a distribution agreement with ATR, an affiliate to closely held EVA Pharma. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes...

November 6, 2025

Developments

Cardiol to present comprehensive findings from Phase II ARCHER trial at ESC M&PD meeting

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) has announced that the full data from ARCHER—a randomized double-blind, placebo-controlled, multi-center Phase II clinical trial of CardiolRx in patients with acute...

November 5, 2025

Developments

Advicenne submits registration application to FDA for Sibnayal in dRTA

Advicenne (Euronext Growth Paris: FR0013296746—ALDVI) has announced the submission of a registration application to the FDA for Sibnayal—a fixed-dose combination of potassium citrate and potassium bicarbonate—for the...

November 5, 2025

Developments

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform. The...

November 5, 2025

Developments

Wellgistics enters LOI to acquire Kare RX digital hub

Wellgistics Health (NASDAQ: WGRX) has announced that it has entered into a non-binding letter of intent (LOI) to acquire Kare RX—an AI-based digital hub—from closely held Kare PharmaTech. According to Wellgistics, Kare...

November 5, 2025

Category - Developments

Subscribe